睿昂基因(688217) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was CNY 64,188,221.36, representing a year-on-year increase of 12.84%[4] - The net profit attributable to shareholders decreased by 58.70% to CNY 533,165.07 compared to the same period last year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses fell by 142.08% to CNY -614,601.26[4] - Basic and diluted earnings per share were both CNY 0.01, down 50.00% year-on-year[5] - The total comprehensive income attributable to the parent company was ¥533,165.07, a decrease of 58.7% from ¥1,290,913.02 in Q1 2023[24] - Basic and diluted earnings per share were both ¥0.01, down from ¥0.02 in the same quarter last year[24] - The company reported a total comprehensive loss of -¥1,437,353.69 for the quarter, compared to a loss of -¥5,300,038.19 in Q1 2023[24] Cash Flow and Investments - The net cash flow from operating activities was CNY 11,518,866.49, a decline of 68.54% year-on-year[5] - In Q1 2024, the company reported a net cash flow from operating activities of ¥11,518,866.49, a decrease of 68.5% compared to ¥36,611,099.54 in Q1 2023[26] - The company experienced a net cash outflow from investing activities of ¥13,134,945.95, an improvement from a net outflow of ¥69,686,922.78 in Q1 2023[28] - The net cash flow from financing activities was -¥15,063,836.61, compared to -¥12,288.24 in the previous year, indicating increased cash outflows[28] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,026,567,072.49, a decrease of 1.68% from the end of the previous year[5] - The total assets as of Q1 2024 amounted to ¥1,026,567,072.49, a decrease from ¥1,044,159,929.12 in the previous year[20] - Total liabilities for Q1 2024 were ¥75,245,107.05, down from ¥76,484,453.94 in Q1 2023[21] - The total equity attributable to shareholders decreased to ¥931,393,288.97 in Q1 2024 from ¥945,776,279.95 in Q1 2023[21] Research and Development - Research and development expenses totaled CNY 16,398,202.66, accounting for 25.55% of operating revenue, an increase of 0.17 percentage points[5] - Research and development expenses increased to ¥16,398,202.66 in Q1 2024, compared to ¥14,436,134.44 in Q1 2023, marking a growth of 13.6%[23] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 4,233[11] - The company plans to repurchase shares with a total fund of no less than RMB 15 million and no more than RMB 20 million, with a maximum repurchase price of RMB 49.00 per share[16] - As of March 29, 2024, the company has repurchased a total of 578,305 shares, accounting for 1.04% of the total share capital, with a total payment of RMB 14,912,378.81[17] Cash and Cash Equivalents - The company's cash and cash equivalents as of March 31, 2024, amounted to RMB 145,081,494.73, compared to RMB 161,676,112.05 on December 31, 2023[18] - The company's cash and cash equivalents at the end of the period were ¥145,047,025.93, down from ¥163,445,523.02 at the end of Q1 2023[28] - The company's cash and cash equivalents increased to ¥82,407,860.90 in Q1 2024, compared to ¥72,363,081.39 in Q1 2023, reflecting a growth of 41.5%[19] Inventory and Accounts Receivable - The inventory level was reported at ¥59,944,143.00 in Q1 2024, slightly down from ¥60,654,837.57 in Q1 2023[19] - The company reported a decrease in accounts receivable to ¥183,424,651.56 in Q1 2024 from ¥187,232,001.40 in Q1 2023[19] Revenue from Sales - Total operating costs for Q1 2024 were ¥64,568,301.80, up from ¥60,723,636.64 in Q1 2023, reflecting a rise of 6.0%[22] - Total revenue from sales of goods and services was ¥57,158,250.16, down 47.3% from ¥108,321,178.65 in the same period last year[26]